Protective effect of sodium–glucose cotransporter 2 inhibitors in patients with rapid renal function decline, stage G3 or G4 chronic kidney disease and type 2 diabetes

AIMS/INTRODUCTION: The risk of end‐stage kidney disease increases in proportion to the decline in the estimated glomerular filtration rate (eGFR). Although protective effects of sodium–glucose cotransporter 2 inhibitors (SGLT2i) on the eGFR decline were shown in several large‐scale clinical trials,...

Descripción completa

Detalles Bibliográficos
Autores principales: Miyoshi, Hideaki, Kameda, Hiraku, Yamashita, Kumiko, Nakamura, Akinobu, Kurihara, Yoshio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6825940/
https://www.ncbi.nlm.nih.gov/pubmed/31026373
http://dx.doi.org/10.1111/jdi.13064

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6825940/
https://www.ncbi.nlm.nih.gov/pubmed/31026373
http://dx.doi.org/10.1111/jdi.13064

Ejemplares similares